Dr. Gabriele Eden

Publikationen

I Originalpublikationen Erst - und Letztautorenschaften / equally contributed

Furlan F, Eden G, Archinti M, Arnaudova R, Andreotti G, Citro V, Cubellis MV, Motta A, Degryse B.
D2A-Ala peptide derived from the urokinase receptor exerts anti-tumoural effects in vitro and in vivo. 
Peptides. 2018; 101:17-24.

Eden G, Archinti M, Arnaudova R, Andreotti G, Motta A, Furlan F, Citro V, Cubellis MV, Degryse B.
D2A sequence of the urokinase receptor induces cell growth through αvβ3 integrin and EGFR. 
Cell Mol Life Sci. 201; 75(10):1889-1907.

Schmidt JJ, Asper F, Einecke G, Eden G, Hafer C, Kielstein JT.
Therapeutic plasma exchange in a tertiary care center: 185 patients undergoing 912 treatments - a one-year retrospective analysis. 
BMC Nephrol. 2018; 19(1):12.

Hafer C, Golla P, Gericke M, Eden G, Beutel G, Schmidt JJ, Schmidt BM, De Reys S, Kielstein JT.
Membrane versus centrifuge-based therapeutic plasma exchange: a randomized prospective crossover study. 
Int Urol Nephrol. 2016; 48(1):133-8.

II Case Reports

Eden G, Kühn-Velten WN, Hafer C, Kielstein JT.
Enhanced elimination of cyclophosphamide by high cut-off haemodialysis: single-dose pharmacokinetics in a patient with cast nephropathy. 
BMJ Case Rep.2018. pii: bcr-2017-221735.

Eden G, Gradaus F, Brown K, Gauert I, Sass C, Kielstein JT.
Plasmapherese zur Behandlung einer hypertriglyzeridämiebedingten Pankreatitis. 
Med Klin Intensivmed Notfmed. 2017;112(5):471-474.

Arelin V, Schmidt JJ, Kayser N, Kühn-Velten WN, Suhling H, Eden G, Kielstein JT.
Removal of methadone by extended dialysis using a high cut-off dialyzer: implications for the treatment of overdose and for pain management in patients undergoing light chain removal. 
Clin Nephrol. 2016;85(6):353-7.